Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery
Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery
复制标题
新辅助化疗和手术治疗食管鳞状细胞癌的肿瘤反应
作者：
Manato Ohsawa;Y. Hamai;M. Emi;Furukawa Takaoki;Y. Ibuki;Kurokawa Tomoaki;Toru Yoshikawa;M. Okada
背景/目的：手术后的新辅助治疗是晚期食管癌的标准治疗方法。本研究旨在评估18F-氟脱氧葡萄糖正电子发射断层扫描预测新辅助化疗病理疗效的潜力。患者和方法：我们纳入了68例晚期食管鳞状细胞癌患者，他们在新辅助化疗前后接受了18F-氟脱氧葡萄糖正电子发射断层扫描，随后接受了手术。对病理疗效进行回顾性分析。结果如下：良好应答者的病理治疗效果与新辅助化疗后的最大标准化摄取值（SUVmax）和SUVmax降低显著负相关（均p<0.0001）。单变量和多变量分析显示，治疗后较低的SUVmax和SUVmax降低是无复发（p=0.02）和总生存期（p<0.0001）的独立预后因素。结论：新辅助化疗后SUVmax及SUVmax降低可预测新辅助化疗的病理疗效。
Background/Aim: Neoadjuvant therapy followed by surgery is the standard treatment for advanced esophageal cancer. This study aimed to evaluated the potential of 18F-fluorodeoxyglucose positron-emission tomography to predict the pathological therapeutic effect of neoadjuvant chemotherapy. Patients and Methods: We enrolled 68 patients with advanced esophageal squamous cell carcinoma who underwent 18F-fluorodeoxyglucose positron-emission tomography before and after neoadjuvant chemotherapy, followed by surgery. Retrospective analysis of the pathological therapeutic effects was performed. Results: The pathological therapeutic effect of good responders was significantly inversely associated with the maximum standardized uptake value (SUVmax) after neoadjuvant chemotherapy and with SUVmax reduction (both p<0.0001). Univariate and multivariate analyses revealed that lower post therapy SUVmax and reduction in SUVmax were independent prognostic factors for relapse-free (p=0.02) and overall survival (p<0.0001). Conclusion: Post-neoadjuvant chemotherapy SUVmax and SUVmax reduction can predict the pathological therapeutic effect of neoadjuvant chemotherapy.
影响因子：
45.3
作者：
Tepper, Joel;Krasna, Mark J.;Mayer, Robert
通讯作者：
Mayer, Robert